Enterprise Value
34.69M
Cash
7.421M
Avg Qtr Burn
-13.18M
Short % of Float
12.65%
Insider Ownership
16.14%
Institutional Own.
15.70%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Olafertinib (CK-101) (EGFR Inhibitor) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 3 Data readout | |
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Failed Discontinued |